


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED**

### **領航醫藥及生物科技有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock Code: 399)**

## **TERMINATION OF SUBSCRIPTION AGREEMENT**

References are made to the announcement of Innovative Pharmaceutical Biotech Limited (the “**Company**”) dated 30 May 2025 (the “**Announcement**”) in relation to, among other matters, the Subscription Agreement and the transactions contemplated thereunder. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as defined in the Announcement.

The Board announces that, after further negotiation and discussion, the Subscriber was unable to carry out his obligations under the Subscription Agreement, taking into account, among other things, the current market condition, the Company and the Subscriber have decided not to proceed with the Subscription. Taking into consideration of the above, on 15 July 2025, the Company and the Subscriber entered into a deed of termination (the “**Deed of Termination**”), pursuant to which the parties to the Subscription agreed that the Subscription Agreement shall be terminated and all the rights, interests, obligations and liabilities of the parties shall cease and determine with effect from 15 July 2025 and no party shall have any claim against the other party in respect of any matter arising out of or in connection with the Subscription Agreement.

The Directors consider that the termination of the Subscription Agreement will not have any material adverse impact on the business operation and financial position of the Group.

By order of the Board  
**Innovative Pharmaceutical Biotech Limited**  
**Yeung Yung**  
*Chairman*

Hong Kong, 15 July 2025

*As at the date of this announcement, the Board comprises Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director), Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkan, Tim (independent non-executive Director), and Ms. Sun Sizheng (independent non-executive Director).*